Portopulmonary hypertension: Current developments and future perspectives.

Area of Science:

• Cardiology
• Pulmonology
• Hepatology

Background:

• Portopulmonary hypertension (POPH) is a severe pulmonary vascular disease secondary to portal hypertension.
• It is a subset of Group 1 pulmonary hypertension (PH) with pathological changes similar to other PH phenotypes.
• POPH leads to increased pulmonary vascular resistance, right ventricular afterload, and potentially fatal right heart failure.

Purpose of the Study:

• To review existing studies on POPH, covering its mechanisms, epidemiology, risk factors, and diagnosis.
• To introduce recent therapeutic interventions for early POPH diagnosis.
• To guide efficient clinical management decisions for POPH patients.

Main Methods:

• Literature review of previous studies on POPH.
• Analysis of biological mechanisms, epidemiology, and risk factors.
• Evaluation of diagnostic approaches and therapeutic interventions.

Main Results:

• POPH prognosis is poor without treatment, and severe cases contraindicate liver transplantation (LT).
• PAH-targeted therapies can optimize pulmonary hemodynamics and reduce mortality risk in POPH patients.
• Early diagnosis and aggressive treatment are crucial for improving outcomes and surgical risk.

Conclusions:

• Early diagnosis and aggressive PAH-targeted therapies are vital for managing POPH.
• Careful selection of liver transplant candidates with POPH is essential for reducing surgical risks.
• Effective clinical management improves outcomes for patients with this severe pulmonary vascular disease.